Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol.

Abstract

Anthracycline, a widely used anti-cancer agent, can elicit irreversible cardiomyopathy called anthracycline-induced cardiomyopathy (ACM). In this report, we describe 5 cases of severe chronic heart failure due to ACM effectively treated with the beta-blocker, carvedilol. Their left ventricular function as well as cardiac symptoms were persistently improved after treatment with carvedilol, suggesting that carvedilol may be an effective therapeutic strategy for ACM as demonstrated in other forms of chronic heart failure.

• Authors: Yasushi Mukai, Tomoki Yoshida, Ryuichi Nakaike, Naoko Mukai, Koji Iwato, Taiichi Kyo, Shunichi Kaseda
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 43 Issue 11 Pg. 1087-8 (Nov 2004) ISSN: 0918-2918 [Print] Japan
• PMID: 15609710 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Anthracyclines
• Carbazoles
• Propanolamines
• Carvedilol

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Adult
• Anthracyclines (adverse effects)
• Carbazoles (therapeutic use)
• Cardiomyopathies (chemically induced, diagnostic imaging, drug therapy)
• Carvedilol
• Echocardiography
• Female
• Heart Failure (chemically induced, diagnostic imaging, drug therapy)
• Humans
• Male
• Middle Aged
• Propanolamines (therapeutic use)
• Treatment Outcome
• Ventricular Dysfunction (chemically induced, diagnostic imaging, drug therapy)
• Ventricular Function, Left (drug effects)